Page 126 - Oncology Coder News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Oncology coder. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Oncology Coder Today - Breaking & Trending Today

'What cool new toys will they come up with': RWJ Barnabas's director of thoracic surgery on the future of cancer tech

There are two things in oncology that excite Joanna Sesti, MD: using new robotic technology and building lasting relationships with her patients. ....

Joanna Sesti , Barnabas Health , N Cooperman Barnabas Medical Center , West Orange , Cooperman Barnabas Medical Center , Cancer Care , Cancer Treatment , Ancer Robot , Cancer Patient , Cancer Director ,

Kwality Pharmaceuticals Himachal Pradesh Facility received EU GMP Approval

Kwality Pharmaceuticals Limited has successfully completed the EU GMP Inspection for its Cephalosporin and Oncology manufacturing unit II at Himachal Pradesh. ....

Himachal Pradesh , Kwality Pharma , Kwality Pharmaceuticals Limited , Kwality Pharmaceuticals Himachal Pradesh Facility , Kwality Pharmaceuticals Ltd , Pharmaceuticals Limited ,

Oncology clinic opens in Charlotte

The practice is open Wednesdays from 8 a.m. to 4 p.m. ....

United States , Sparrow Eaton , Sparrow Medical Group Oncology Charlotte , Seaton Hospital , Medical Group Oncology Charlotte , Local News , Sparrow Eaton Hospital ,

Tislelizumab for advanced esophageal squamous cell carcinoma

1. Median overall survival was 17.2 months in the tislelizumab group versus 10.6 months in the placebo group (HR 0.66). 2. Both groups experienced similar rates of grade 3 or worse treatment-related adverse events. Evidence Rating Level: 1 (Excellent) Study Rundown: Current first-line treatment options for esophageal cancer have limited efficacy, but recent research has ....

Rating Level , Advanced Esophageal Cancer , Esophageal Cancer , Chronic Disease ,

Previously treated advanced endometrial cancer treated with lenvatinib plus pembrolizumab results in greater survival than chemotherapy alone

1. Overall survival is longer for patients receiving a combination of lenvatinib plus pembrolizumab as compared with chemotherapy treatment alone 2. Progression-free survival was greater in the group receiving combination therapy Evidence Rating Level: 1 (Excellent) Study Rundown: This study examined whether treatment with the combination of lenvatinib plus pembrolizumab provided greater benefits for survival ....

Minute Medicine Inc , Rating Level , Advanced Endometrial Cancer , Endometrial Cancer , Lenvatinib And Pembrolizumab , Chronic Disease ,